Skip to main content
Hanshang Group Co.,Ltd. logo

Hanshang Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600774 ISIN · CNE000000NC5 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,577 across all filing types
Latest filing 2021-03-02 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600774

About Hanshang Group Co.,Ltd.

https://www.whhsg.com/

Hanshang Group Co.,Ltd. is a diversified enterprise focused on commercial operations, exhibition services, and healthcare. The company manages a portfolio of large-scale department stores, shopping malls, and specialized retail outlets. Its exhibition segment provides comprehensive venue management and event organization services for international and domestic trade fairs. Hanshang Group has significantly expanded its presence in the healthcare sector through the development and distribution of pharmaceuticals, medical devices, and health-related products. By integrating traditional commercial assets with modern biomedical research and health management services, the group targets a broad consumer base and professional medical markets, emphasizing a strategic transition toward a comprehensive health-oriented business model.

Recent filings

Filing Released Lang Actions
汉商集团关于全资子公司与关联方签订《委托管理合同》暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related-party transaction involving a wholly-owned subsidiary of the company and an affiliated party. It details the signing of an entrustment management contract to avoid competition between the controlling shareholder and the listed company. The document includes descriptions of the contract, parties involved, pricing policy, impact on the company, and approvals by the board and independent directors. It is a formal disclosure of a related-party transaction rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document is a regulatory announcement about a related-party transaction, fitting best under Regulatory Filings (RNS).
2021-03-02 Chinese
汉商集团第十届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 汉商集团股份有限公司, detailing the approval of a related party transaction involving a wholly-owned subsidiary. It includes information about the meeting date, voting results, and mentions the involvement of independent directors. The document is short (620 characters) and focuses on board decisions rather than financial results or detailed management reports. It does not contain financial statements or detailed analysis, nor is it a report publication announcement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2021-03-02 Chinese
汉商集团关于为子公司提供担保进展情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of guarantees provided by the company for its subsidiary. It details the guarantee amount, the guaranteed party, and related financial data. It is a regulatory announcement about the company's external guarantees and does not contain financial statements or detailed financial performance data. The document is relatively short (1438 characters) and serves as a disclosure of guarantee status rather than a full financial report or audit. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-02-02 Chinese
2020年年度业绩预增公告
Earnings Release Classification · 95% confidence The document is titled as a 2020 annual performance forecast announcement by 汉商集团股份有限公司. It provides estimated net profit figures for the full year 2020, compares them to the previous year, and explains the reasons for the expected increase. It explicitly states that the forecasted results are preliminary and unaudited, and that the final audited 2020 annual report will be disclosed later. The document is relatively short (1834 characters) and serves as an earnings forecast or performance guidance rather than a full financial report. It does not contain actual audited financial statements or comprehensive financial data. Therefore, it fits best as an Earnings Release (ER) type, which covers initial announcements of quarterly or periodical financial results or forecasts with key highlights only. FY 2020
2021-01-18 Chinese
非公开发行股票申请文件二次反馈意见的回复
Regulatory Filings Classification · 95% confidence The document is a detailed response to the China Securities Regulatory Commission's second feedback on a non-public stock issuance application by 汉商集团股份有限公司 (Hanshang Group Co., Ltd.). It discusses the use of raised funds for acquiring 100% equity of a pharmaceutical company, details about financing, loan arrangements, financial data, risks related to the issuance, and compliance with regulatory requirements. The content is focused on the application and approval process for a non-public stock issuance, including detailed explanations and clarifications to regulatory feedback. This type of document is typically classified as a Regulatory Filing (RNS) because it is a regulatory submission responding to feedback on a capital raising filing, not the actual capital raising announcement or a financial report. It is not an earnings release, annual report, or other financial report, but a regulatory compliance document related to capital raising and acquisition.
2021-01-03 Chinese
关于《中国证监会行政许可项目审查二次反馈意见通知书》之反馈意见回复的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Han Shang Group regarding their response to a second feedback notice from the China Securities Regulatory Commission (CSRC) related to their non-public stock issuance application. It references regulatory review and disclosure obligations but does not contain financial statements or detailed financial data. The document is short (577 characters) and primarily serves as a regulatory update and disclosure of the company's reply to regulatory feedback. It does not constitute a full report like an Annual Report or Interim Report, nor is it a certification letter or voting result. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2021-01-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.